Depatment of Bioengineering, Yıldız Technical University, Istanbul, Turkey.
Department of Ophthalmology, Ümraniye Trn. And Rch. Hospital, Istanbul, Turkey.
J Ocul Pharmacol Ther. 2020 Sep;36(7):487-496. doi: 10.1089/jop.2019.0137. Epub 2020 May 21.
Diabetes mellitus (DM) is a metabolic disease, which is the most common cause of low vision in developing countries and affects almost all systems of the body. In view of the increase in DM prevalence in the world, it would not be a surprise that diabetic retinopathy (DR) and other vascular complications related to diabetes become a serious public health problem. Currently, vascular endothelial growth factor, laser photocoagulation, and intravitreal steroids are the mainstays for DR treatment, but the efficacy of these treatment strategies remains insufficient. Therefore, new treatment modalities for DR have been developed, such as stem cell therapies, extracellular vesicular system, and nanodrug delivery systems. Although there have been several reviews in the literature on the treatment of DR, we have not confronted any review that has the titles of all these topics. With this review, we aim to present the pathophysiology of DR and to review the current and promising new treatment methods based on stem cells, extracellular vesicular system, and nanodrug delivery systems for the future of DR management.
糖尿病(DM)是一种代谢疾病,是发展中国家低视力最常见的原因,几乎影响身体的所有系统。鉴于世界上 DM 的患病率增加,如果糖尿病视网膜病变(DR)和其他与糖尿病相关的血管并发症成为严重的公共卫生问题,也不会令人惊讶。目前,血管内皮生长因子、激光光凝和眼内类固醇是 DR 治疗的主要方法,但这些治疗策略的疗效仍然不足。因此,已经开发出 DR 的新治疗方法,例如干细胞疗法、细胞外囊泡系统和纳米药物递送系统。尽管文献中有几篇关于 DR 治疗的综述,但我们没有遇到任何一篇标题涵盖所有这些主题的综述。通过本次综述,我们旨在介绍 DR 的病理生理学,并根据基于干细胞、细胞外囊泡系统和纳米药物递送系统的现有和有前途的新治疗方法,为 DR 的未来管理提供参考。